• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

    10/2/25 7:57:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QNTM alert in real time by email

    TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today that it has received two key final reports related to its potential breakthrough drug for Multiple Sclerosis: the 90-day oral toxicity study report and the toxicokinetic study report for Lucid-21-302 ("Lucid-MS"). These studies were commissioned to provide key data to support an Investigational New Drug (IND) application with the US FDA for a phase-2 clinical trial in Multiple Sclerosis.

    "We are pleased that we now have the final reports for these toxicity studies, as this represents an important milestone," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. "These reports will be used to support Quantum's IND application to the US FDA, further advancing the Lucid-MS drug development program."

    Anthony Durkacz, Executive Co-Chairman of Quantum BioPharma added, "We are very excited about the potential of Lucid-MS as a first-in-class treatment for MS targeting demyelination. With these final reports, we move significantly closer to initiating our Phase 2 trial of Lucid-MS in people with Multiple Sclerosis."

    About Quantum BioPharma Ltd.

    Quantum BioPharma (NASDAQ:QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at www.unbuzzd.com. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

    For more information visit www.quantumbiopharma.com.

    Forward-Looking Information

    This press release contains certain "forward-looking statements" within the meaning of applicable securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as "believes", "hopes", "alleges", "pending", "further", or variations of such words and phrases or statements that certain actions events or results "may", "could", "which", or "will" and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements regarding: the Company's ongoing litigation against major financial institutions; the potential outcome or judgment value; expectations regarding whistleblower submissions and related rewards; continued market integrity initiatives; future business performance and possible acquisitions.

    In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the ability to obtain and validate whistleblower evidence; the timing and outcome of legal proceedings; resolution of ongoing litigation on favourable terms, availability and sufficiency of litigation funding; continued regulatory compliance and market stability for the Company's operations.

    The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the adverse outcome of legal actions; the receipt and credibility of whistleblower disclosures; changes in applicable laws and regulations; the actions of third parties involved in alleged manipulation; evolving market dynamics; the sufficiency of future litigation proceeds to fund the Company's whistleblower reward; the continued ability to obtain sufficient litigation funding; limited future growth opportunities, and reliance on key personnel.

    Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.

    The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

    Contacts:

    Quantum BioPharma Ltd.

    Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board

    Email: [email protected]  

    Telephone: (833) 571-1811

    Investor Relations

    Investor Relations: [email protected]

    General Inquiries: [email protected]    



    Primary Logo

    Get the next $QNTM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNTM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

    TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today that it has received two key final reports related to its potential breakthrough drug for Multiple Sclerosis: the 90-day oral toxicity study report and the toxicokinetic study report for Lucid-21-302 ("Lucid-MS"). These studies were commission

    10/2/25 7:57:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, welcomes Dr. Jack Antel as new clinical advisor to its multiple sclerosis (MS) program centered around Lucid-21-302 ("Lucid-MS"), a patented, new chemical entity investigational drug designed to inhibit demyelination in MS. Dr Antel will be advising Quantum Biopharma on t

    10/1/25 7:50:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

    TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today the results of its annual general and special meeting of shareholders, held on Friday, September 26, 2025 in person at 801-1 Adelaide Street East, Toronto, ON M5C 2V9 ("AGSM"). There were shareholders represented in person or by proxy at t

    9/29/25 7:40:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    SEC Filings

    View All

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    10/2/25 7:57:03 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    10/1/25 7:50:06 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    9/29/25 7:40:05 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Financials

    Live finance-specific insights

    View All

    Quantum BioPharma Makes Strategic Investment in GameStop Corp.

    TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE:GME) to hold on the Company's balance sheet as a strategic investment. This move aligns with Quantum BioPharma's ongoing commitment to combating market corruption and enhancing shareholder value through prudent financial strategies and advocacy against manipulative trading practices. The Company has been at the forefront of fighting market corruption, as evidenced by

    7/22/25 7:00:00 AM ET
    $GME
    $QNTM
    Electronics Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

    TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce its intention to declare a special dividend consisting of Contingent Value Rights (the "CVRs") to be issued on a 1:1 basis to holders of the Company's Class B Subordinate Voting Shares. Each CVR will entitle the holder to receive a pro rata portion of a minimum of 10% and a maximum of 50% of the net proceeds, ultimately recovered by the Company, if any, in connection with its legal action against CIBC World Markets, RBC D

    6/13/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time

    TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) "Quantum BioPharma" or the "Company"), today announced it will host a Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern time to discuss its recent year-end financial results, regulatory initiatives, commercial-readiness activities and anticipated milestones. Quantum BioPharma CEO, President, & Executive Co-Chair Zeeshan Saeed and Head of Finance and M&A Jason Sawyer will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed following the

    4/24/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

    TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today the results of its annual general and special meeting of shareholders, held on Friday, September 26, 2025 in person at 801-1 Adelaide Street East, Toronto, ON M5C 2V9 ("AGSM"). There were shareholders represented in person or by proxy at t

    9/29/25 7:40:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

    TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management. About Mr. Kevin Malone Mr. Malone is a 2nd generation financial advisor with over 40 years of family experience in wealth management. This combined with his deep entrepreneurial background he launched Malone Wealth in 2021. Mr. Malone focuses deeply on pattern recognition skills and data research to diffe

    4/22/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors

    TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company. Mr. Terry Lynch Mr. Lynch is widely known and respected for his role founding and operating Save Canadian Mining, a not-for-profit organization leading the fight against micro-cap stock market manipulation and naked short selling. Mr. Lynch has a long,

    3/27/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care